{"id":"xelox-bevacizumab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hand-foot syndrome"},{"rate":"10-30%","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, thereby inhibiting DNA replication and transcription. Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), preventing its interaction with its receptor and thereby inhibiting angiogenesis.","oneSentence":"Oxaliplatin and capecitabine inhibit DNA replication and transcription, while bevacizumab targets vascular endothelial growth factor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:05.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT05171660","phase":"PHASE3","title":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-02-08","conditions":"Colorectal Cancer Stage IV","enrollment":446},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06801665","phase":"PHASE2","title":"FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis","status":"RECRUITING","sponsor":"Hua Jiang","startDate":"2025-04-17","conditions":"Colon Cancer Liver Metastases","enrollment":30},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT07233850","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-11","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":300},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":"Hepatocellular Carcinoma(HCC)","enrollment":300},{"nctId":"NCT07025239","phase":"PHASE3","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Metastatic Colorectal Cancer","enrollment":430},{"nctId":"NCT04856787","phase":"PHASE2, PHASE3","title":"A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-06-22","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":62},{"nctId":"NCT01792934","phase":"NA","title":"Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2013-05","conditions":"Multi-organ Metastatic Colorectal Cancer","enrollment":478},{"nctId":"NCT06858969","phase":"PHASE2","title":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-09","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06843954","phase":"PHASE4","title":"Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mohammed Mahmood Mohammed","startDate":"2022-09-01","conditions":"Colo-rectal Cancer","enrollment":157},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT06282445","phase":"PHASE2","title":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-03-01","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06808412","phase":"PHASE2","title":"To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer","status":"RECRUITING","sponsor":"xiaohua li","startDate":"2024-07-05","conditions":"Rcctal Cancer","enrollment":118},{"nctId":"NCT06422403","phase":"PHASE2","title":"A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-11-25","conditions":"Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":360},{"nctId":"NCT03511963","phase":"PHASE3","title":"A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2018-04-09","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":677},{"nctId":"NCT06139211","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-03","conditions":"Advanced Solid Tumor","enrollment":186},{"nctId":"NCT01531595","phase":"PHASE2","title":"Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pia Osterlund","startDate":"2012-02","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT04940546","phase":"PHASE1, PHASE2","title":"Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-16","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT04547166","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2021-03-10","conditions":"Metastatic Colorectal Cancer","enrollment":568},{"nctId":"NCT06493760","phase":"PHASE2","title":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-09-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06547385","phase":"PHASE1","title":"Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-01-13","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT06513221","phase":"PHASE2","title":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-25","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT06115174","phase":"PHASE4","title":"Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-11-01","conditions":"Metastatic Colorectal Carcinoma","enrollment":44},{"nctId":"NCT04659382","phase":"PHASE2","title":"Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2020-10-07","conditions":"Metastatic Colorectal Cancer, pMMR, MSS","enrollment":52},{"nctId":"NCT04262687","phase":"PHASE2","title":"Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate","status":"UNKNOWN","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2021-04-06","conditions":"Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable","enrollment":55},{"nctId":"NCT03950154","phase":"PHASE3","title":"Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Colorectal Cancer","enrollment":198},{"nctId":"NCT05970302","phase":"PHASE2","title":"XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-07","conditions":"Tislelizumab, Bevacizumab, Oxaliplatin","enrollment":52},{"nctId":"NCT05799820","phase":"PHASE2","title":"QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-09-29","conditions":"Colorectal Carcinoma","enrollment":60},{"nctId":"NCT04194359","phase":"PHASE2","title":"Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-02-04","conditions":"Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable","enrollment":25},{"nctId":"NCT05544812","phase":"","title":"A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-05-01","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT05409417","phase":"PHASE2, PHASE3","title":"Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":40},{"nctId":"NCT05077839","phase":"PHASE2","title":"Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-09-01","conditions":"First-line Treatment, Advanced Colorectal Cancer","enrollment":184},{"nctId":"NCT00655499","phase":"PHASE2","title":"Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-06","conditions":"Colorectal Cancer","enrollment":65},{"nctId":"NCT01006369","phase":"PHASE2","title":"Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2009-05","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT04324476","phase":"PHASE2","title":"A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2019-09-01","conditions":"Advanced Colorectal Cancer","enrollment":50},{"nctId":"NCT00984048","phase":"","title":"Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2009-08","conditions":"Colorectal Cancer","enrollment":160},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT02119026","phase":"PHASE2","title":"Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Prof. Dr. Werner Scheithauer","startDate":"2011-02","conditions":"Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT03645876","phase":"PHASE2","title":"SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-11-08","conditions":"Metastatic Colorectal Cancer","enrollment":12},{"nctId":"NCT01588990","phase":"PHASE4","title":"A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-26","conditions":"Colorectal Neoplasms","enrollment":128},{"nctId":"NCT01506167","phase":"","title":"An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07-06","conditions":"Colorectal Cancer","enrollment":719},{"nctId":"NCT03511183","phase":"PHASE2","title":"XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Harbin Medical University","startDate":"2018-03-01","conditions":"Colorectal Neoplasms, Chemotherapy","enrollment":66},{"nctId":"NCT00642603","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Colorectal Cancer","enrollment":41},{"nctId":"NCT01493713","phase":"PHASE4","title":"Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2011-11-16","conditions":"Colorectal Cancer, Hepatic Metastasis","enrollment":83},{"nctId":"NCT02026583","phase":"PHASE2","title":"A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2013-12","conditions":"Colorectal Cancer","enrollment":43},{"nctId":"NCT01279681","phase":"PHASE3","title":"Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2011-01","conditions":"Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity","enrollment":32},{"nctId":"NCT00408772","phase":"PHASE2","title":"Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2007-06","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":""},{"nctId":"NCT00127036","phase":"PHASE2","title":"Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2003-10","conditions":"Adenocarcinoma, Colon Cancer","enrollment":65},{"nctId":"NCT00700570","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Colorectal Cancer","enrollment":45},{"nctId":"NCT00069095","phase":"PHASE3","title":"A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-07","conditions":"Colorectal Cancer","enrollment":2035},{"nctId":"NCT01320683","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2011-03","conditions":"Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer","enrollment":1},{"nctId":"NCT00920868","phase":"PHASE1","title":"XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib","status":"COMPLETED","sponsor":"Herbert Hurwitz, MD","startDate":"2009-05","conditions":"Solid Tumor, Metastatic Colorectal Cancer","enrollment":22},{"nctId":"NCT00577031","phase":"PHASE4","title":"OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Colorectal Cancer","enrollment":205},{"nctId":"NCT01818973","phase":"PHASE2","title":"Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-03","conditions":"Rectal Cancer","enrollment":45},{"nctId":"NCT01071655","phase":"PHASE2","title":"Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2010-02","conditions":"Colorectal Cancer","enrollment":195},{"nctId":"NCT02075086","phase":"PHASE2","title":"Angiogenic Switch in Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Grupo Hospital de Madrid","startDate":"2011-07","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT01135498","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-11","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT01077739","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT00646607","phase":"PHASE3","title":"FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2007-06","conditions":"Colon Cancer","enrollment":3756},{"nctId":"NCT01159171","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-01","conditions":"Colorectal Cancer","enrollment":50},{"nctId":"NCT00499369","phase":"PHASE3","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":72},{"nctId":"NCT00394992","phase":"PHASE3","title":"Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer","status":"TERMINATED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2006-12","conditions":"Colorectal Cancer, Liver Metastases","enrollment":79},{"nctId":"NCT01962376","phase":"PHASE4","title":"Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis","status":"UNKNOWN","sponsor":"Hebei Medical University","startDate":"2013-02","conditions":"Gastric Cancer, Liver Metastasis","enrollment":60},{"nctId":"NCT00909987","phase":"PHASE2","title":"Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2009-03","conditions":"Rectum Cancer","enrollment":46},{"nctId":"NCT00112918","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-12","conditions":"Colorectal Cancer","enrollment":3451},{"nctId":"NCT00598156","phase":"PHASE3","title":"Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2007-06","conditions":"Metastatic Colorectal Cancer","enrollment":249},{"nctId":"NCT00755534","phase":"PHASE2","title":"Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-11","conditions":"Colorectal Cancer","enrollment":68},{"nctId":"NCT00444041","phase":"PHASE1, PHASE2","title":"Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Austrian Society Of Surgical Oncology","startDate":"2007-01","conditions":"Metastatic Colorectal Cancer","enrollment":43},{"nctId":"NCT01763450","phase":"PHASE2","title":"Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2012-09","conditions":"Liver Metastases, Colorectal Cancer","enrollment":100},{"nctId":"NCT00378066","phase":"PHASE2","title":"Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-08","conditions":"Metastatic Colorectal Cancer","enrollment":49},{"nctId":"NCT00784446","phase":"PHASE1, PHASE2","title":"First-line Therapy of Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2008-04","conditions":"Stage IV Colorectal Cancer","enrollment":51},{"nctId":"NCT00849550","phase":"PHASE1","title":"Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Herbert Hurwitz","startDate":"2009-07","conditions":"Unspecified Adult Solid Tumor, Protocol Specific, Cancer","enrollment":32},{"nctId":"NCT00478634","phase":"PHASE1","title":"A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-05","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors","enrollment":19},{"nctId":"NCT00349336","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Colorectal Cancer","enrollment":64},{"nctId":"NCT01679327","phase":"PHASE2","title":"Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT01453257","phase":"PHASE2","title":"Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Progression Free Survival","enrollment":72},{"nctId":"NCT01024504","phase":"PHASE2","title":"Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2006-03","conditions":"Metastatic Colorectal Cancer","enrollment":46},{"nctId":"NCT00557713","phase":"PHASE2","title":"XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","status":"UNKNOWN","sponsor":"Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials","startDate":"2007-02","conditions":"Rectal Neoplasms, Locally Advanced Rectal Adenocarcinoma","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XELOX + bevacizumab","genericName":"XELOX + bevacizumab","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Biologic","firstApprovalDate":"","aiSummary":"Oxaliplatin and capecitabine inhibit DNA replication and transcription, while bevacizumab targets vascular endothelial growth factor. Used for Metastatic colorectal cancer, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}